These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 37147690)

  • 41. The pharmacotherapeutic options in patients with catecholamine-resistant vasodilatory shock.
    Albertson TE; Chenoweth JA; Lewis JC; Pugashetti JV; Sandrock CE; Morrissey BM
    Expert Rev Clin Pharmacol; 2022 Aug; 15(8):959-976. PubMed ID: 35920615
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early Use of Norepinephrine in Septic Shock Resuscitation (CENSER). A Randomized Trial.
    Permpikul C; Tongyoo S; Viarasilpa T; Trainarongsakul T; Chakorn T; Udompanturak S
    Am J Respir Crit Care Med; 2019 May; 199(9):1097-1105. PubMed ID: 30704260
    [No Abstract]   [Full Text] [Related]  

  • 43. The Role of Angiotensin II in Poisoning-Induced Shock-a Review.
    Chen A; Wong A
    J Med Toxicol; 2022 Apr; 18(2):145-154. PubMed ID: 35258848
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial.
    Torgersen C; Dünser MW; Wenzel V; Jochberger S; Mayr V; Schmittinger CA; Lorenz I; Schmid S; Westphal M; Grander W; Luckner G
    Intensive Care Med; 2010 Jan; 36(1):57-65. PubMed ID: 19756505
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low-dose vasopressin in the treatment of vasodilatory septic shock.
    Malay MB; Ashton RC; Landry DW; Townsend RN
    J Trauma; 1999 Oct; 47(4):699-703; discussion 703-5. PubMed ID: 10528604
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Angiotensin II and Vasopressin for Vasodilatory Shock: A Critical Appraisal of Catecholamine-Sparing Strategies.
    Heavner MS; McCurdy MT; Mazzeffi MA; Galvagno SM; Tanaka KA; Chow JH
    J Intensive Care Med; 2021 Jun; 36(6):635-645. PubMed ID: 32223515
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of the Addition of Angiotensin II in Patients With Shock After Cardiac Surgery at a Veterans Affairs Medical Center.
    Bird S; Chand M; Tran TL; Ali S; Awad SS; Cornwell LD; Schutz A; Jimenez E
    Ann Pharmacother; 2023 Feb; 57(2):141-147. PubMed ID: 35658717
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of dopamine and norepinephrine in the treatment of shock.
    De Backer D; Biston P; Devriendt J; Madl C; Chochrad D; Aldecoa C; Brasseur A; Defrance P; Gottignies P; Vincent JL;
    N Engl J Med; 2010 Mar; 362(9):779-89. PubMed ID: 20200382
    [TBL] [Abstract][Full Text] [Related]  

  • 49. VASOPRESSOR-RESISTANT HYPOTENSION, COMBINATION VASOPRESSOR THERAPY, AND SHOCK PHENOTYPES IN CRITICALLY ILL ADULTS WITH VASODILATORY SHOCK.
    Priyanka P; Chang CH; Chawla LS; Kellum JA; Clermont G; Murugan R
    Shock; 2022 Oct; 58(4):260-268. PubMed ID: 36018286
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-Dose IV Hydroxocobalamin (Vitamin B12) in Septic Shock: A Double-Blind, Allocation-Concealed, Placebo-Controlled Single-Center Pilot Randomized Controlled Trial (The Intravenous Hydroxocobalamin in Septic Shock Trial).
    Patel JJ; Willoughby R; Peterson J; Carver T; Zelten J; Markiewicz A; Spiegelhoff K; Hipp LA; Canales B; Szabo A; Heyland DK; Stoppe C; Zielonka J; Freed JK
    Chest; 2023 Feb; 163(2):303-312. PubMed ID: 36174744
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Angiotensin II for the treatment of distributive shock in the intensive care unit: A US cost-effectiveness analysis.
    Busse LW; Nicholson G; Nordyke RJ; Lee CH; Zeng F; Albertson TE
    Int J Technol Assess Health Care; 2020 Apr; 36(2):145-151. PubMed ID: 32114996
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Studies in clinical shock and hypotension. 3. Comparative effects of vasopressor drugs and dextran.
    Cohn JN; Luria MH
    Arch Intern Med; 1965 Oct; 116(4):562-6. PubMed ID: 4284276
    [No Abstract]   [Full Text] [Related]  

  • 53. Response to dopamine vs norepinephrine in tricyclic antidepressant-induced hypotension.
    Tran TP; Panacek EA; Rhee KJ; Foulke GE
    Acad Emerg Med; 1997 Sep; 4(9):864-8. PubMed ID: 9305427
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Incidence of hypotension according to the discontinuation order of vasopressors in the management of septic shock: a prospective randomized trial (DOVSS).
    Jeon K; Song JU; Chung CR; Yang JH; Suh GY
    Crit Care; 2018 May; 22(1):131. PubMed ID: 29784057
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Renin Levels and Angiotensin II Responsiveness in Vasopressor-Dependent Hypotension.
    See EJ; Chaba A; Spano S; Maeda A; Clapham C; Burrell LM; Liu J; Khasin M; Liskaser G; Eastwood G; Bellomo R
    Crit Care Med; 2024 Aug; 52(8):1218-1227. PubMed ID: 38511994
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Outcomes Associated With Norepinephrine Use Among Cardiac Intensive Care Unit Patients with Severe Shock.
    Burstein B; Vallabhajosyula S; Ternus B; Murphree D; Barsness GW; Kashani K; Jentzer JC
    Shock; 2021 Oct; 56(4):522-528. PubMed ID: 34524266
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Blast From the Past: Revival of Angiotensin II for Vasodilatory Shock.
    Bissell BD; Browder K; McKenzie M; Flannery AH
    Ann Pharmacother; 2018 Sep; 52(9):920-927. PubMed ID: 29582666
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial.
    Gordon AC; Mason AJ; Thirunavukkarasu N; Perkins GD; Cecconi M; Cepkova M; Pogson DG; Aya HD; Anjum A; Frazier GJ; Santhakumaran S; Ashby D; Brett SJ;
    JAMA; 2016 Aug; 316(5):509-18. PubMed ID: 27483065
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Delayed vasopressor initiation is associated with increased mortality in patients with septic shock.
    Colon Hidalgo D; Patel J; Masic D; Park D; Rech MA
    J Crit Care; 2020 Feb; 55():145-148. PubMed ID: 31731173
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The ATHOS-3 trial, angiotensin II and The Three Musketeers.
    Bellomo R; Hilton A
    Crit Care Resusc; 2017 Mar; 19(1):3-4. PubMed ID: 28215124
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.